come from hard work by people in the British Toxicology Society and in industrial laboratories to validate the fixed dose procedure, from the support of official bodies, and from some encouragement (and some disparagement) by animal welfare groups. The important general conclusion seems to be that changes in animal experimentation are most likely to be achieved on the basis of clear evidence of utility and when alI concerned understand the purposes and limitations of the alternative procedure. 
Leukaemia and cancer chemotherapy
The risk is acceptably small but may be reducible further
In the past 15 years cytotoxic chemotherapy has revolutionised the prognosis for patients with some kinds of tumours. Because of this clinicians are now paying far more attention to the long term risks of such treatment, including leukaemia, sterility, cardiopulmonary disease, and altered immunity. 3 Reports have compared the incidence of leukaemia in patients treated for various cancers with that in healthy populations and have examined the actuarial incidence of leukaemia in subgroups receiving different treatments.45 This approach, however, does not overcome one source of potential biasthat, for instance, Hodgkin's disease itself or certain stages of the disease may be associated with an increased risk of leukaemia.
More recently, Kaldor et al reported two studies-one in Hodgkin's disease6 and the other in ovarian cancer7-that overcame this problem by using a case-control design within large populations of patients with these two tumours. They found 114 cases of leukaemia in 99 113 survivors of ovarian cancer and matched each of these with three (four in the case of 35 283 German patients) patients without leukaemia.8 For Hodgkin's disease they found 163 cases of leukaemia among 29552 patients, and these were each matched with three controls with Hodgkin's disease without leukaemia.
In the study of ovarian cancer, chemotherapy alone was associated with a 12-fold increase in relative risk compared with surgery alone. Patients receiving chemotherapy and radiotherapy had a relative risk of 100; radiotherapy alone did not increase the risk above that of surgery. All alkylating agents clearly increased the risk of leukaemia, as did the combination of doxorubicin and cisplatin.
For Hodgkin's disease chemotherapy alone was associated with a relative risk of leukaemia of 9 0 as compared with radiotherapy alone. Patients treated with both modalities did not have a further increase in risk, though treatment with more than six cycles of nitrogen mustard and procarbazine increased the relative risk to 14-0. Radiotherapy caused a dose related increase in risk. When adjustment was made for the chemotherapy used there was a twofold increase in risk of leukaemia in those who had had a splenectomy.
In general these reports confirm the results of previous cohort studies,45 but they do not provide a precise estimate of the risk of leukaemia as there was appreciable heterogeneity of the rates of leukaemia depending on the source of the data. Most data were from population based cancer registries, but some were from single institutions. The crude incidence of leukaemia was eight times higher in single hospitals than in registries for ovarian carcinoma; the comparable figure for Hodgkin's disease showed a near fourfold difference. These data might possibly reflect patient selection and more intensive treatment in single institutions, but an alternative explanation is that there was underrecognition of a second malignancy in patients from tumour registries. Supporting this hypothesis is the finding that nine of 11 cases of myelodysplastic syndrome in patients with ovarian cancer occurred in one institution that accounted for 4% of the patients. What, then, is the risk that chemotherapy will induce leukaemia, and does cost-benefit analysis suggest that such chemotherapy should continue to be used? As a corollary to this, can the therapeutic efficacy of chemotherapy be maintained while its toxicity is reduced? Data from multiple studies in ovarian cancer suggest that the risk of leukaemia is four to five times that in a normal population. The risk is almost entirely related to exposure to alkylating agents, though Kaldor et al also implicate the combination of cisplatin and doxorubicin,7 a finding recently reported by others.9 The risk rises with total dose used.37 For patients with Hodgkin's disease given chemotherapy the risk in Kaldor's study was a little over five times that in those receiving radiotherapy alone. 6 The actuarial risk of leukaemia five to 10 years after treatment for Hodgkin's disease is 2-10%,"10 and a second solid malignancy has been increasingly reported.' 5 Cost-benefit analysis in advanced Hodgkin's disease clearly favours chemotherapy: the risk of drug induced leukaemia is relatively small, and such treatment greatly increases the chances of long term survival. Before the introduction of effective chemotherapy survival in patients with advanced disease was less than 5% at five years -nowadays over half of such patients survive long term.'2 The data of Kaldor et al may, however, provide a further argument for the trend away from splenectomy, and they certainly argue against unnecessarily prolonged chemotherapy and for the move towards regimens that result in less exposure to alkylating agents and so in lower rates of leukaemia and sterility. I3
The results are less clear for patients with advanced ovarian carcinoma, in whom prolonged survival after chemotherapy is uncommon. No single randomised study has been large enough to identify the most effective type of chemotherapy, though cisplatin combinations are commonly recommended. A meta-analysis of over 50 randomised studies is in progress and should provide clearer guidance. 14 The risk of leukaemia remains small, and the data suggest that there is a clear benefit for some form of chemotherapy, but as prolonged treatment with alkylating agents has been shown to result in an increasing risk ofleukaemia such treatment should be avoided when possible.
The potential for chromosomal damage and the development of myelodysplatic syndrome have been recognised as risks of chemotherapy for some years. 5'8 Chromosomal changes characteristic of leukaemia have been identified in patients treated with cytotoxic agents,'9 and these include damage to genes concerned with haemopoietic regulation.2" Thus chromosomal changes may be useful in the early detection of the risk of leukaemia and for selecting cytotoxic combinations with a low risk.
The studies of Kaldor et al emphasise the importance of the long term consequences of the treatment of cancer. In ovarian carcinoma the challenge is to develop more effective treatment; the induction of second malignancy is of subsidiary importance, at least in advanced disease. But now that Hodgkin's disease is cured in about 70% of cases the problem of second malignancy and other long term consequences is assuming much greater importance.2' The challenge here is to modify treatment to reduce the risk of leukaemia and other complications while maintaining effectiveness; for instance, less leukaemogenic combinations already developed also reduce the incidence of sterility in men and are as effective as the conventional four drug regimen mechlorethamine, procarbazine, vincristine, and prednisone-MOPP. Other strategies, such as avoiding splenectomy, may need to be considered. As a research tool chromosomal changes may prove to be helpful in the early selection of chemotherapy regimens least likely to induce malignancy. Patients who can benefit from a hearing aid are not suitable for a cochlear implant. It is only the very profoundly deaf who should be referred. The special government funds are on the point of being distributed, but centres where these patients can be considered include Manchester, Nottingham, Cambridge, and three hospitals in London: University College Hospital, St Mary's, and Guy's. The list will no doubt increase continuously as the commercial application of this work is extended.
The publicity surrounding the secretary of state's announcement showed the way that advances occur in our society: through a shifting coalition of pressure groups presided over by governments anxious to follow prevailing trends. Publicity does, however, sometimes create confusion as to the facts. People with severe sensorineural deafness cannot be helped by conventional surgery and have to rely on hearing aids. Even these are useless to patients who have no hearing left at all, but in such patients electrical stimulation of the cochlea will be perceived as buzzing sounds. Efforts over the past 10 years have concentrated on making these sounds meaningful and related to the speech that has initiated them. The apparatus used has consisted, therefore, of an implanted electrode and an external box (about the size of a pocket calculator), which processes sounds into electrical signals.
Ten years ago several research groups throughout the world began work on these problems in different ways -in most cases in association with one of several important commercial companies that began to produce appliances. Facing inordinate costs in both production and marketing, many of these groups fell by the wayside, and, though there are competitors, by far the most successful has been the Australian company Cochlear. It has marketed a multichannel prosthesis that gives consistent results and it also provides technical support through a widespread marketing operation. Cochlear's prostheses are the ones most likely to be implanted in Britain in any numbers. The electrodes are inserted part of the way along the cochlea through the round window, and speech sounds are processed to extract the fundamental frequencies, thus presenting the patterns of speech.
Another prosthesis, this time from the United States, uses four intracochlear electrodes presenting speech sounds filtered into different bands, and this, too, has given excellent results (D K Eddington, National Institutes of Health consensus development conference on cochlear implants, Washington, DC, May 1988). It has no substantial marketing network in Britain and may find it difficult to establish itself.
Prostheses using cochlear electrodes cost around £10000 each, not counting other costs. Virtually all patients find that they are helped in lip reading by the sounds they hear, and perhaps a quarter to a third may be able to follow conversation without lip reading. One or two have communicated on the telephone.
Nevertheless, anxieties about invasion of the cochlea have led some research groups to try another approach -extracochlear stimulation. This has been investigated in Britain by a group from University College Hospital and the Royal National Institute for the Deaf by using a single channel.2
